Barroso-Sousa R - Search Results

1

Evidence to date: talazoparib in the treatment of breast cancer.

Exman P, Barroso-Sousa R, Tolaney SM. Exman P, et al. Onco Targets Ther. 2019 Jul 2;12:5177-5187. doi: 10.2147/OTT.S184971. eCollection 2019. Onco Targets Ther. 2019. PMID: 31303769 Free PMC article. Review.

2

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.

Barroso-Sousa R, Shapiro GI, Tolaney SM. Barroso-Sousa R, et al. Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Epub 2016 Jun 22. Breast Care (Basel). 2016. PMID: 27493615 Free PMC article. Review.

3

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Barroso-Sousa R, et al. JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064. JAMA Oncol. 2018. PMID: 28973656 Free PMC article.

4

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.

Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L. Lee H, et al. Cancer Immunol Res. 2017 Dec;5(12):1133-1140. doi: 10.1158/2326-6066.CIR-17-0208. Epub 2017 Oct 27. Cancer Immunol Res. 2017. PMID: 29079654 Free PMC article.

5

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Barroso-Sousa R, et al. Cancer. 2018 Mar 15;124(6):1111-1121. doi: 10.1002/cncr.31200. Epub 2018 Jan 3. Cancer. 2018. PMID: 29313945 Free article. Review.

6

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.

Barroso-Sousa R, Exman P, Tolaney SM. Barroso-Sousa R, et al. Future Oncol. 2018 Apr;14(10):937-945. doi: 10.2217/fon-2017-2500. Epub 2018 Mar 28. Future Oncol. 2018. PMID: 29589471 Review.

7

Database Selection and Heterogeneity-More Details, More Credibility-Reply.

Barroso-Sousa R, Barry WT, Tolaney SM. Barroso-Sousa R, et al. JAMA Oncol. 2018 Sep 1;4(9):1295-1296. doi: 10.1001/jamaoncol.2018.1231. JAMA Oncol. 2018. PMID: 29955794 No abstract available.

8

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Chang LS, et al. Endocr Rev. 2019 Feb 1;40(1):17-65. doi: 10.1210/er.2018-00006. Endocr Rev. 2019. PMID: 30184160 Free PMC article. Review.

9

Optimal treatment of early stage HER2-positive breast cancer.

Pernas S, Barroso-Sousa R, Tolaney SM. Pernas S, et al. Cancer. 2018 Dec 1;124(23):4455-4466. doi: 10.1002/cncr.31657. Epub 2018 Oct 6. Cancer. 2018. PMID: 30291791 Free article. Review.

10

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. Barroso-Sousa R, et al. Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047. Ann Oncol. 2019. PMID: 30753274 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters